The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Procalcitonin
研究概览
简要总结
This study aims to establish whether tocilizumab has any significant effect on procalcitonin levels on patients diagnosed with COVID-19 pneumonia requiring intensive care admission. The effects on other biochemical and clinical markers are also considered.
详细描述
A retrospective study, involving the first fifty patients treated with tocilizumab for acute deterioration in COVID-19 pneumonia in the Intensive Care Unit (ICU) at Mater Dei Hospital in Malta.
The following parameters will be collected from medical records:
- procalcitonin levels, daily for twenty days or until discharge or death.
- namely white cell count (WCC), neutrophils, lymphocytes,
- C-reactive protein (CRP)
- PaO2/FiO2 ratio (P/F ratio).
This group will be compared to a control group was chosen from patients admitted to the ICU who were not eligible for tocilizumab treatment, matched to the study group for age, gender, mode of ventilation required and length of stay in ICU.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 16 Years 至 100 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed COVID-19 diagnosis
- •Admitted to ITU
- •Tocilizumab treatment
排除标准
- 未提供
研究组 & 干预措施
TCZ
The first 50 patients admitted to the ITU at Mater Dei Hospital with COVID-19 Pneumonia, to whom tocilizumab was administered
干预措施: Tocilizumab (Drug)
结局指标
主要结局
Procalcitonin
时间窗: throughout study completion, daily for maximum of 20 days
effect of Tocilizumab on Procalcitonin levels
次要结局
- P/F ratio(throughout study completion, daily for maximum of 20 days)
- CRP(throughout study completion, daily for maximum of 20 days)
- WCC(throughout study completion, daily for maximum of 20 days)
- NLR(throughout study completion, daily for maximum of 20 days)
- Neutrophils(throughout study completion, daily for maximum of 20 days)
- Lymphocytes(throughout study completion, daily for maximum of 20 days)
研究者
Stephen Sciberras
Investigator
Sciberras, Stephen M.D.